Abstract
Premature ovarian insufficiency (POI) occurs in at least 1% of all women and causes life-long health problems and psychological stress. Infertility caused by POI used to be considered absolute, with infertility treatment having little or no value. Generally, it has been thought that medicine can provide little service to these patients. The etiology of POI has been found to be genetic, chromosomal, and autoimmune. In addition, the increasing numbers of cancer survivors are candidates for iatrogenic POI, along with patients who have undergone ovarian surgery, especially laparoscopic surgery. Over 50 genes are known to be causally related to POI, and the disease course of some cases has been clarified, but in most cases, the genetic background remains unexplained, suggesting that more genes associated with the etiology of POI need to be discovered. Thus, in most cases, the genetic background of POI has not been clarified. Monosomy X is well known to manifest as Turner’s syndrome and is associated with primary amenorrhea, but recent studies have shown that some women with numerical abnormalities of the X chromosome can have spontaneous menstruation up to their twenties and thirties, and some even conceive. Hormone replacement therapy (HRT) is recommended for women with POI from many perspectives. It alleviates vasomotor and genitourinary symptoms and prevents bone loss and cardiovascular disease. POI has been reported to reduce quality of life and life expectancy, and HRT may help improve both. Most of the problems that may occur with HRT in postmenopausal women do not apply to women with POI; thus, in POI, HRT should be considered physiological replacement of estrogen (+progesterone). This review describes some new approaches to infertility treatment in POI patients that may lead to new treatments for POI, along with the development of more sensitive markers of secondary/preantral follicles and genetic diagnosis.
Highlights
The diagnosis of premature ovarian insufficiency (POI) is a serious event for a woman
Among the women with abnormal karyotypes and secondary amenorrhea, a significant proportion of patients were older than 35 years at the onset of amenorrhea, so an age limit for testing for chromosomal abnormalities should not be set in diagnosing patients with POI (Table 2) [10, 11, 13]
In addition to these autoantibodies, it has been reported that autoantibodies directed to different targets, including the luteinizing hormone (LH) receptor, Follicle stimulating hormone (FSH) receptor, and zona pellucida are defectable in POI [42,43,44]
Summary
The diagnosis of premature ovarian insufficiency (POI) is a serious event for a woman. It is a condition with medical, psychological, and reproductive implications. POI is a state in which ovarian function decreases irreversibly beyond the extent of the normal range for the women’s age. It can manifest as primary or secondary amenorrhea. A number of papers used FSH levels >40, 50, or 20 mIU/ml as the criteria based on older reports, but some patients with POI sometimes show FSH levels lower than these cut-off levels. Luborsky et al reported that the incidence of POI was 1.1% in 2003 in a cross-sectional study. The prevalence of POI may have ethnic and/or regional differences and change with time due to lifestyle and/or environmental factors that still need to be further investigated
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
